Medications and Monitoring in Treatment of Nontuberculous Mycobacterial Pulmonary Disease

Alice Sawka; Andrew Burke

doi:10.1016/j.ccm.2023.06.012

Medications and Monitoring in Treatment of Nontuberculous Mycobacterial Pulmonary Disease

Clin Chest Med. 2023 Dec;44(4):815-828. doi: 10.1016/j.ccm.2023.06.012. Epub 2023 Aug 14.

Authors

Alice Sawka¹, Andrew Burke²

Affiliations

¹ Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia; University of Adelaide, Adelaide, South Australia, Australia.
² University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia; Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia. Electronic address: andrew.burke@health.qld.gov.au.

PMID: 37890918
DOI: 10.1016/j.ccm.2023.06.012

Abstract

In the treatment of nontuberculous mycobacteria (NTM) lung disease, clinicians must consider potential toxicities that may occur as a result of prolonged exposure to a multidrug antibiotic regimen. Frequent clinical and microbiological monitoring is required to assess response and guide treatment duration. This article summarizes toxicity profiles of the antibiotics that are most frequently prescribed for the treatment of NTM lung disease. The role of therapeutic drug monitoring during use of amikacin and linezolid is discussed. The available evidence to guide frequency and extent of medication monitoring during NTM treatment is provided.

Keywords: Aminoglycoside; Mycobacterium abscessus; Mycobacterium avium; Nontuberculous mycobacteria; Therapeutic drug monitoring.

Publication types

Review

MeSH terms

Anti-Bacterial Agents / adverse effects
Humans
Lung
Lung Diseases* / drug therapy
Lung Diseases* / microbiology
Mycobacterium Infections, Nontuberculous* / drug therapy
Mycobacterium Infections, Nontuberculous* / microbiology
Nontuberculous Mycobacteria

Substances

Anti-Bacterial Agents